In a prespecified secondary analysis of 4579 high bleeding risk patients after PCI (1428 with CKD), 1-month vs standard antiplatelet therapy gave similar NACE in CKD (HR 0.91) and non-CKD patients (HR 0.96), with lower bleeding in both groups.
Secondary analysisn = 4,579
Landi et al. Abbreviated or standard antiplatelet therapy after PCI in HBR patients with chronic kidney disease: a prespecified analysis from the MASTER DAPT trial